Welcome to our dedicated page for Benitec Biopharm SEC filings (Ticker: BNTC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Benitec Biopharma Inc. (NASDAQ: BNTC) SEC filings page on Stock Titan provides direct access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. As a clinical-stage, gene therapy-focused biotechnology company, Benitec uses its SEC reports to outline progress on its Silence and Replace DNA-directed RNA interference (ddRNAi) platform, the clinical development of its lead candidate BB-301 for Oculopharyngeal Muscular Dystrophy (OPMD)-related dysphagia, and its financial position.
Key filings include annual reports on Form 10‑K, which summarize full-year financial results, research and development expenses related primarily to BB-301, and broader operational updates. Quarterly reports on Form 10‑Q provide interim financial statements, cash and cash equivalents balances, and management’s discussion of ongoing clinical and corporate activities. These documents allow readers to track how Benitec funds and advances its Silence and Replace-based therapeutics over time.
Benitec also files current reports on Form 8‑K to announce material events. Recent 8‑K filings have covered topics such as positive interim clinical results from the BB-301 Phase 1b/2a trial, the FDA’s Fast Track Designation for BB-301, equity financings through underwritten and registered direct offerings, and board appointments. The company’s Definitive Proxy Statement on Schedule 14A discloses information on governance, director elections, executive compensation, equity incentive plans, and the annual meeting of stockholders.
On Stock Titan, these filings are complemented by AI-powered summaries that highlight important points from lengthy documents, such as clinical development updates, changes in cash runway, or terms of financing transactions. Users can quickly review 10‑K and 10‑Q reports with AI-generated insights, and scan Form 8‑K items for material agreements, capital raises, and regulatory news. Where applicable, Form 4 insider transaction reports can also be monitored to see how directors and officers transact in BNTC shares.
For investors analyzing Benitec’s gene therapy pipeline and financial condition, this SEC filings page offers a structured view of real-time EDGAR updates, summarized by AI, making it easier to understand the implications of complex regulatory documents without reading every line of each filing.
Benitec Biopharma Inc. furnished an update on its business by issuing a press release with financial results for its full year ended June 30, 2025 and an operational update. The company attached this press release as Exhibit 99.1 to the current report and specified that this information is being furnished under the results of operations and financial condition item, rather than treated as filed for liability purposes or automatically incorporated into other documents.
Benitec Biopharma Inc. (BNTC) is an early-stage genetic medicines company developing BB-301 for Oculopharyngeal Muscular Dystrophy (OPMD). BB-301 has received Orphan Drug Designation in the United States and the European Union and is in a Phase 1b/2a single-arm, open-label, sequential dose-escalation study (NCT06185673) with dosing delivered directly to pharyngeal muscles and interim safety/efficacy readouts expected at 180-day intervals.
Financially, the company reported $97.7 million in cash and cash equivalents as of June 30, 2025, used cash in operations of $23.6 million for the year, and raised material proceeds during the year (including a $40.0 million PIPE and additional offerings), with total net proceeds from issuances and warrant exercises during the fiscal year stated at $70.5 million. The company disclosed a restatement related to prior-period recognition of certain non-cash share-based compensation expenses and notes it will continue to incur operating losses and depend on financing to fund operations.
Janus Henderson Group plc and its affiliate Janus Henderson Biotech Innovation Master Fund Ltd report beneficial ownership stakes in Benitec Biopharma Inc. Janus Henderson Group is reported to beneficially own 2,902,794 shares, equal to 11.3% of the common stock, with shared voting and shared dispositive power over those shares. The Biotech Innovation Master Fund is reported to beneficially own 2,193,481 shares, equal to 8.6% of the common stock, also held with shared voting and dispositive power.
The filing includes an explicit certification that the securities are held in the ordinary course of business and were not acquired for the purpose of changing or influencing control of the issuer. The filing identifies the reporting persons as an investment adviser/holding company and an investment vehicle.
Janus Henderson Group plc and an affiliated fund report beneficial holdings in Benitec Biopharma Inc. common stock (CUSIP 08205P209). The filing shows Janus Henderson Group plc with 25,600,210 shares of shared voting and dispositive power, representing 11.3% of the class. An affiliated vehicle, Janus Henderson Biotech Innovation Master Fund Ltd, reports 2,193,481 shares (shared voting and dispositive power), representing 8.6%. The schedule includes a certification that the securities were acquired in the ordinary course of business and a power of attorney executed by Janus Henderson Group plc authorizing named attorneys-in-fact to file required ownership reports.